Siemens (NYSE:SI) Healthineers business said this week it won FDA approval for its Mammomat Revelation mammography system.
The newly cleared mammography system includes the company’s InSpect integrated specimen imaging tool and a new HD breast biopsy solution that allows for one-click targeting of suspicious areas, Siemens said.
The integrated InSpect tool enables imaging and real-time review of biopsy samples at the device’s workstation. Siemens touted that its HD breast tomosynthesis system allows the widest image acquisition angle at 50 degrees.
“Mammomat Revelation is another example of Siemens Healthineers innovation that aids in early breast cancer detection. Building on the industry’s widest angle in breast tomosynthesis, Mammomat Revelation delivers an improved patient experience. For the first time, healthcare providers have next-generation tools that make a real difference in diagnostic certainty,” Siemens Healthineers NA X-ray VP Martin Silverman said in a prepared statement.
Earlier this month, Siemens Healthineers shares gained nearly 7% after raising more than $5 billion in an initial public offering.
